Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI (PHOTO)

Lyon (ots) - Hitachi, Ltd. (TSE:6501, "Hitachi") and Centre Léon Bérard (CLB), a
leading French Comprehensive Cancer Center in Lyon-France, announced today that
they have entered into an agreement to jointly promote research and development
aimed at improving the efficiency of diagnosis and treatment of cancer and
established a new research laboratory called Hitachi Lyon Lab on the CLB site,
starting November 5th.

In this collaboration, Hitachi and CLB will conduct research and development of
novel technologies to detect and diagnose cancers exploiting medical images such
as CT/MRI using artificial intelligence (AI) and to predict response to
radiation therapy using tumor genomic and transcriptomic data.

According to statistics from the Organization for Economic Co-operation and
Development (OECD), Japan has the largest number of CTs and MRIs per million
people. With the improvements of diagnostic imaging equipment, the number of
images read by radiologists is increasing, and technologies that reduce the
burden on radiologists using artificial intelligence are being actively
developed. In addition, as a result of dramatic progress in gene analysis
technology in recent years, it has become possible to analyse individual genome
information at low cost, and personalized medicine that provides medical care
suitable for each individual has been a key concern mainly in developed
countries.

Hitachi provides solutions that improve the quality and efficiency of medical
care, from diagnostic/clinical fields such as diagnostic imaging equipment and
particle therapy systems to informatics fields such as IT and AI. In addition,
Hitachi has been contributing to maintaining and improving people's quality of
life by delivering particle therapy systems to a number of world-renowned
hospitals, where more than 60,000 people have been treated with Hitachi's
systems so far.

CLB is a Comprehensive Cancer Center in Lyon - Auvergne-Rhône-Alpes region,
France, whose missions are care, research and education. It is affiliated to
UNICANCER, the French Comprehensive Cancer Centers federation, counting twenty
other cancer centers. CLB provides state-of-the-art diagnosis and treatment for
cancer patients such as innovative therapies and radiation therapy. Images, as
well as molecular data from tumors, are collected and stored overtime for
research purpose, upon consent from patients. Hitachi and CLB will conduct joint
research at Hitachi Lyon Lab to improve the efficiency of diagnosis and
treatment of cancer, by combining CLB's clinical expertise and patient data
related to cancer treatment with Hitachi's know-how in diagnostic imaging and
IT/AI. Specifically, they will jointly develop diagnostic imaging technologies
to detect potential cancer sites and assist radiologists' diagnosis from image
data such as CT and MRI using AI. Identification of biomarkers exploiting
genomic data in the context of resistance will allow to predict responses and
prognoses upon radiation treatment.

Hitachi will continue to accelerate global R&D with advanced medical
institutions and universities in the healthcare field, and will work with
partners in joint research to create new value and contribute to improving the
quality and efficiency of care.

About Hitachi Ltd

http://ots.ch/BuVlvx

About Hitachi Medical Systems Europe

http://ots.ch/8VxUEP

About Centre Léon Bérard

http://ots.ch/KOZJ1X

Pressekontakt:
Contact:

Hitachi Medical Systems Europe Holding AG
Romea Wallnoefer
Tel: +41 41 748 63 33
r.wallnoefer@hitachi-medical-systems.com

Centre Léon Bérard
Nathalie Blanc
Tel: +33 (0)4 78 78 51 43
nathalie.blanc@lyon.unicancer

Original-Content von: Hitachi Medical Systems Europe Holding AG, übermittelt durch news aktuell